Theryte Ltd was founded as a Liverpool based, venture capital backed biotechnology spin-out from the University of Liverpool in June 1998, to develop new cancer diagnostics and delivery systems. The Company has been built on the pioneering work of Professor Hilmar Warenius, who has developed a radically new, breakthrough understanding of cancer, and how new therapeutic agents can be developed to treat established cancers. In addition to directing research and development, Professor Warenius brings to the company his many years experience as a clinical oncologist. The Company has recently refocused its activities, securing IP assets and accelerating drug discovery efforts. Value will be created through the assembly of a group of managers and scientific technologists to commercialise the Company's technology and products. A new strategic plan has been approved for major growth to create new drugs and complete serial licensing deals with large biotechnology and pharmaceutical companies. A chemical development program has yielded the Company's lead candidate, THR-53, which kills cancer cells but does not affect normal cells. Death of the cancer cells takes place over a period of weeks after ‘programming' through initial treatment over just one or two days. The Company has raised over £2.0 million pounds so far from grants and private investors, through a number of small rounds, the most recent of which was completed in January 2007, with support from Esperante BV , Fenwall Investments and the Founder. The Directors are: Mr Peter Dohrn (Chairman), Prof. Hilmar Warenius (Chief Medical Officer & Director of R&D), Mr Dean Slagel (nominated by Esperante), Mr Andrew Douglas (nominated by Fenwall). , src= , src= , src=
http://www.pivotalbiosciences.com
Pivotal BioSciences, Inc. is an emerging company dedicated to the development and commercialization of innovative cancer therapies. Breakthroughs in the basic understanding of the immune system, combined with powerful new biotechnological tools, have provided the foundation for new, rational, and technologically sophisticated approaches to immunotherapy. In the mid-‘90s when it became apparent that cancer tumor growth is angiogenesis-dependent (new blood vessel formation), scientists began to understand the mechanisms by which tumor growth is stimulated by angiogenesis. Pivotal BioSciences is pioneering the effort to develop powerful new compounds to control this process and thereby cut off the blood supply to growing tumors. The product candidates developed by Pivotal's distinguished founders were discovered at the University of Southern California Keck School of Medicine. Pivotal's strategy is to initiate early-stage clinical trials and then obtain commercialization partners to complete advanced clinical trials, obtain FDA approval, manufacture and market its highly promising drug candidates.
VectorLogics, Inc., a Delaware corporation, is a privately-held biotechnology firm based in Birmingham, Alabama. The Company was founded in 1998 by David T. Curiel, MD, PhD. VLI is focused on developing products for the treatment of cancer and liver diseases using attenuated viral delivery systems. The cancer products are highly-selective (recognizing cancer cells - avoiding normal cells) and highly-specific (active in cancer cells - inactive in normal cells). Such products should, in the words of the American Association for Cancer Research (AACR), be "radically cleaner, more precise therapies." The first product candidate that VLI has under development is an oncolytic virotherapeutic for the treatment of ovarian and brain cancer. This treatment uses a conditionally replicative, targeted adenovector and is delivered to the tumor region to kill the cancer cells. Outstanding proof of principle has already been seen in ovarian cancer and gliomas predicting that the increased efficacy and safety of our unique patented approach will yield similar success in the treatment of other cancers. VLI expects to receive an IND allowance to commence Phase I trials in Q1 2007 for the ovarian cancer indication using regional delivery of this drug candidate. VLI's second product candidate is an orally-administered hepatitis therapeutic vaccine based on attenuated avian virus (IBDV) that causes no disease in humans. A phase II clinical trial conducted in Hungary reported the safety and efficacy of IBDV superinfection therapy in 42 acute hepatitis patients (HBV and HCV). IBDV showed stable, significant clinical improvement and long-lasting remission in a phase I clinical trial in decompensated chronic hepatitis patients as well. Superinfection therapy combined with oral delivery of this novel drug candidate has the potential to treat chronic HBV and HCV hepatitis, and other viral pathogens affecting about 600 million people worldwide. The first product will capitalize on the absence of effective treatment for chronic hepatitis. VectorLogics plans to design and conduct Phase II and Pivotal clinical trials to develop and test the IBDV superinfection therapy in chronic hepatitis patient non-responsive to conventional (IFN-based) treatments.
CG Therapeutics, Inc. is a biotechnology company founded in 2005 in Seattle, Washington, to bring effective new cancer therapeutics to market. The company's products will combat hCG, a powerful hormone secreted by cancer cells to promote their growth and spread. The first of these products, CG201, is a cancer vaccine that is distinctly different from other cancer vaccines. Unlike the majority of cancer vaccine candidates, CG201 stimulates a patient's immune system to produce antibodies that create anti-tumor effects comparable to the widely used monoclonal antibody products Avastin®, Herceptin®, and Erbitux®. CGT is heir to twenty years of previous development of anti-hCG vaccines, including $30 million of prior investment by government agencies, universities, and corporations. The company's lead product, CG201, is ready to enter late-stage clinical testing. The vaccine has an excellent safety profile and appeared to extend cancer patient's survival in previous Phase 2 clinical trials.
http://www.oncotherapeutics.com
Oncotherapeutics is a full service Contract Research Organization (CRO) with a unique focus on the therapeutic oncology area. This specialized approach offers a strategic advantage to our clients in the pharmaceutical, biotechnology and device industries. With expertise in phase I-IV clinical trials and pharmacokinetic studies, we offer a wide array of services that are custom tailored to meet your needs. Our comprehensive program encompasses laboratory research, protocol concept, design and development, clinical trial management, monitoring, data management, biostatistics, safety review, clinical and database auditing, medical monitoring and medical writing. Nationally recognized research oncologists and key opinion leaders in the oncology field oversee senior level clinical research teams. We completely plan, conduct, execute, validate, analyze, prepare and finalize clinical study reports for submission. Oncotherapeutics has successfully conducted a multitude of oncology studies in the areas of multiple myeloma, myelodysplastic syndrome, monoclonal gammopathy of undetermined significance (MGUS), melanoma, non-small cell lung cancer (NSCLC), breakthrough cancer pain, other hematologic malignancies, and metastatic bone disease. Our proven track record of client satisfaction and success is a testament to our commitment to the highest standards of innovation, support and return on investment. We look forward to helping you achieve your goals.
http://www.pnptherapeutics.com
PNP Therapeutics®, Inc. is an emerging biotechnology company engaged in the research and development of a platform technology and proprietary products for the treatment of cancer. At the center of PNP's System is a patented enzyme (E. coli purine nucleoside phosphorylase), that has been shown to work with a variety of well-characterized nucleoside prodrugs. In addition, PNP Therapeutics® is developing several of its own prodrugs for which patent protection will be sought. PNP Therapeutics® is the exclusive licensee of several patents owned jointly by the University of Alabama at Birmingham Research Foundation and Southern Research Institute of Birmingham Alabama that cover the Company's technology. Many common cancers (including prostate, breast, colon, lung, brain, melanoma, pancreas, ovarian, kidney) can progress to become untreatable and eventually kill the patient. There are compounds that could abolish these tumors, but are much too toxic to administer systemically to cancer patients. PNP is predicated on the notion that solid tumors can be compelled to create their own chemotherapy, and thus elicit their own self-destruction. We have shown that this sort of chemotherapy is remarkably potent, abolishes otherwise refractory human cancers, and can be used safely because it is produced within the tumor mass.
The Ontario Cancer Research Network is a non-for-profit organization working to speed the development and testing of new cancer therapies and make Ontario an international leader in translational cancer research. OCRN is providing funds for research, supporting and streamlining the clinical trials system, building a comprehensive tumor bank and creating a better source of information for Ontarians with cancer seeking to enter a clinical trial. OCRN is supported by $100 million in funding from the Ontario Ministry of Enterprise, Opportunity and Innovation.
PhytoCeutica is dedicated to the development of Traditional Chinese Medicine (TCM) into FDA-approved prescription drugs for the treatment of cancer. Utilizing the highest scientific standards to assess safety, efficacy and quality control, PhytoCeutica focuses on relevant preclinical studies, rigorous clinical investigations and a novel platform technology to assess botanical quality control and reproducibility. Chinese medicine has a long, rich and well-respected history with roots that go back thousands of years. Combining this ancient experience-based knowledge with objective, evidence-based scientific studies will engender botanical formulations with a proven, therapeutic utility for treating serious, life-threatening diseases. PhytoCeutica is actively pursuing FDA approval for its lead herbal formulation, PHY906, as a patented broad-spectrum adjuvant with conventional chemotherapy. With compelling pre-clinical studies completed and an advanced quality control platform developed, FDA-allowed Phase I/II clinical studies are currently being conducted. PhytoCeutica is among the leaders in developing high quality botanical medicines of the future. With an experienced management team, board of directors and advisors, PhytoCeutica is pursuing strategic partnerships with Asia, EU and the US to develop an exciting new class of FDA approved prescription medicines.
Syndax Pharmaceuticals, Inc., was founded in 2005 to extend and improve the lives of cancer patients by developing and commercializing novel therapies. Our vision is boldâ€"to modify the tumor phenotype, allowing for new therapeutic opportunities that restore or extend the benefit of targeted therapies. Our vision is practicalâ€"to develop effective regimens that have broad commercial potential by optimizing features important to patients, physicians, and payers.
Sirtex Medical Limited is an Australia-based biotechnology and medical device company. The Company is engaged in the manufacturing, distributing and conducting research and development (R&D) leading to commercialization of liver cancer treatments utilizing small particle technology to a number of markets in Asia-Pacific, Europe and the United states of America. (Source: ARS)
Pharminox was formed in 2002 as a spin-out from Oxford University. We are focused on the discovery and development of novel small molecule drugs for the treatment of cancer. In early 2004, Malcolm Stevens, Director of the Cancer Research UK Experimental Cancer Chemotherapy Group, joined Pharminox as Chief Scientific Officer. Our discovery activities are now based at our new laboratories at the BioCity facility in the centre of Nottingham. We have world class expertise in medicinal chemistry and our approach to drug discovery is very much chemistry-driven. We are progressing a number of innovative discovery programmes which include completely new classes of anti-cancer agent with novel mechanisms of action, offering the prospect of first in class compounds. Over time we intend to build our pipeline through continuing internal drug discovery combined with selective acquisition of appropriate external research and development opportunities. Our in-licensing activities are intended to identify late stage discovery and early stage clinical development programmes which can complement our own internal activities, thus creating an innovative drug development portfolio ranging from early stage discovery through to clinical proof of concept. We have an experienced management team, led by Peter Worrall, with the expertise and collaborative network to undertake, on a virtual basis, the complicated process of drug development. With our people and our portfolio we believe that we have in place the building blocks to become a major force in oncology research and development within the UK over the next few years.
TRACON Pharmaceuticals, Inc. is a biotechnology company developing targeted therapies for cancer and related diseases. We address unmet needs in this arena with product candidates that focus on cellular targets primarily implicated in cancer growth and angiogenesis. Currently, TRACON is focused on the development of several drug candidates fitting this profile, all of which are at an early stage of development. We believe that these treatments have the potential to offer benefits far exceeding those provided by cytotoxic cancer treatments and first generation targeted therapies. Further, our drug candidates have been selected, in part, for their potentially advantageous side effect profile and will be developed with the goal, among other goals, of expanding the standard of care by combining easily with existing therapies. Our mission is to become a premier therapeutics company in oncology and related diseases. Our vision is to develop and commercialize targeted therapeutic products in underserved indications to maximize patient benefit and enhance shareholder value. In order to achieve this goal, our strategy is to: recruit a senior management team with a proven track record of success developing targeted therapeutics; apply our development expertise to develop and commercialize our drug candidates; leverage resources through collaborations and outsourcing; and enhance our pipeline by in-licensing additional attractive drug candidates. We have established partnerships with academic and commercial entities that have identified candidates in late preclinical or early clinical development for cancer and angiogenesis. Our business model is designed to avoid the expense and risk inherent in internal drug discovery programs and attempts to maximize value by improving upon identified candidates with appropriate scientific, development and commercial expertise, in order to advance them through preclinical development and clinical trials. We will attempt to optimize compounds by identifying clear clinical and regulatory pathways forward, strengthening and developing intellectual property ownership, and conducting pre-clinical and clinical development to produce pharmaceuticals that add value for patients, physicians and shareholders. TRACON was formed in New York, in October 2004, as Lexington Pharmaceuticals, Inc., a Delaware corporation. In March 2005, the Company's name was changed to TRACON Pharmaceuticals, Inc., and it moved from New York to San Diego, California. Dr. Bertrand C. Liang was named President and CEO of the Company at that time. With the initial infrastructure of the Company established over the ensuing year, Dr. Charles P. Theuer replaced Dr. Liang as President and CEO in July 2006.
Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company's products are based on the EVadeÔ Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases. The EVadeÔ Ribonuclease technology is covered by patents acquired by the Company through an exclusive license with the University of Wisconsin. The Company is in the late pre-clinical stages of development of QBI-139 and is expecting to file an Investigational New Drug Application in the first half of 2008. Phase I human clinical trials are expected to begin soon after filing the IND. Second generation products are under development and pre-clinical work is ongoing.
Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include a) the Ras pathway program with a small molecule clinical candidate with selective anti-tumor activity, b) the colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. Prolexys' ability to identify and validate novel therapeutic targets is driven by its technological leadership in the field of proteomics and the application of proteomics technologies to its own, and its partners, drug discovery programs. Prolexys has developed two key technologies, a high throughput yeast 2 hybrid system called HyNet, and a mass spectrometry-based protein science technology called HySpec, that complement one another and provide a powerful approach for identifying novel molecular targets relevant to the treatment of human disease. In addition, Prolexys has developed HyScreen, to validate the therapeutic utility of these novel targets as well as in house high-throughput screening, in vivo pharmacology, medicinal chemistry, and drug development capabilities. Prolexys was formed in 2001 with investments from Myriad Genetics, Inc., Hitachi Ltd., Friedli Corporate Finance, A.G., and Oracle Corporation. The company is privately held and located in Salt Lake City, Utah.
CELATOR® is a privately held biopharmaceutical company working to develop new and more effective combination therapies to treat cancer. CombiPlexSM/TM, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies. Based on the strength of the CombiPlex technology platform, Celator is positioned to develop a range of products targeting many different forms of cancer. The Company's development program already includes several promising combination therapy product candidates: CPX-1 (Irinotecan HCI-Floxuridine ) is in Phase 2 clinical development as a treatment for colorectal cancer.
Endocyte is also developing powerful companion diagnostic agents (such as EC20 and EC0652) that are designed to predict (in advance) if a patient will respond to our drug therapy. By linking our drug guidance system to a diagnostic imaging agent, we can generate a patient specific targeting profile to help identify likely responders (click to see image).
Chlorogen, Inc. is a biotechnology company that specializes in the expression of pharmaceutical proteins in the chloroplasts of plants. Through its patented chloroplast transformation technology, Chlorogen is committed to being a world-class producer of beneficial proteins for human therapy. In addition to co-developing our own pharmaceutical pipeline, we are selectively outlicensing CTTÔ technology for use in other markets, such as food and feed and biodefense.
OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. Encouraging preliminary data from four of the Phase 2 studies has been reported in 2007. OGX 427 has begun evaluation in Phase 1 clinical studies, while our third product candidate, OGX-225, has completed preclinical pharmacology studies.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory